Denali Therapeutics Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) N/A -€39.74M -76.8% N/A N/A N/A
    (estimated) €406.61M +123.5% -€171.55M -53.0% -42.2% +1.6 pp N/A N/A
    (estimated) €181.95M +145.8% -€364.70M -14.1% -200.4% +3.7 pp €988.57M +202.6% 543.3% +1.0 pp
    (estimated) €74.04M +1,428.2% -€424.69M -3.5% -573.6% +85 pp €326.68M -163.0% 441.2% +110 pp
    (estimated) €4.84M +∞% -€440.21M +22.1% -9,086.3% -91 pp -€518.59M +83.3% -10,704.2% -110 pp
    €0.00 -100.0% -€360.60M +191.1% N/A -€282.99M -3.8% N/A
    €281.93M +204.7% -€123.87M -55.5% -43.9% +2.6 pp -€294.31M +52.1% -104.4% +1.0 pp
    €92.51M +122.9% -€278.05M +12.2% -300.6% +3.0 pp -€193.52M +11.8% -209.2% +2.1 pp
    €41.51M -85.5% -€247.85M -508.5% -597.2% -6.2 pp -€173.05M -148.4% -416.9% -5.4 pp
    €286.30M +1,158.2% €60.68M -136.0% 21.2% +7.6 pp €357.60M -413.7% 124.9% +6.3 pp
    €22.76M -79.3% -€168.56M +445.3% -740.7% -7.1 pp -€114.00M -349.8% -501.0% -5.4 pp
    €110.17M +∞% -€30.91M -58.9% -28.1% -0.28 pp €45.64M -172.5% 41.4% +0.41 pp
    €0.00 +NaN% -€75.22M +1.8% N/A -€62.91M +11.4% N/A
    €0.00 +NaN% -€73.91M +416.2% N/A -€56.49M +452.3% N/A
    €0.00 -€14.32M N/A -€10.23M N/A

    Notifications